Future mRNA therapeutic platforms remain to be explored in the following directions: 1) selective organ targeting (SORT) technology needed to be detailed in the LNP corona composition 2) personalized framework 3) reprogramming the tumor microenvironment, to promote CD4+ and CD8+ cells infiltrates in the tumors 4) biodegradablity and biocompatibility, covalently coupling degradable chemical groups to reduce cytotoxicity 5) pharmacokinetics and pharmacodynamics, appropriate duration of pharmacological effects, and 6) adjuvanticity, the relationship between innate immune and inflammation. This evidence concerns the gene CD8A and neoplasm.